Nirsevimab-a breakthrough in respiratory syncytial virus bronchiolitis

Zein Assad¹, Jesse Papenburg², Naïm Ouldali³

Affiliations

¹ Department of General Pediatrics, Pediatric Infectious Disease and Internal Medicine, Robert Debré University Hospital, APHP, Paris, France; Department of Pediatrics, Cayenne Hospital, Cayenne, French Guiana, France; Infection, Antimicrobials, Modelling, Evolution Research Unit, INSERM UMR 1137, Paris Cité University, 75018 Paris, France; Groupe de Pathologie Infectieuse Pédiatrique, Nice, France. Electronic address: zein.assad@aphp.fr.
² Division of Pediatric Infectious Diseases, Department of Pediatrics, Montreal Children's Hospital of the McGill University Health Centre, Montreal, QC, Canada.
³ Department of General Pediatrics, Pediatric Infectious Disease and Internal Medicine, Robert Debré University Hospital, APHP, Paris, France; Infection, Antimicrobials, Modelling, Evolution Research Unit, INSERM UMR 1137, Paris Cité University, 75018 Paris, France; Groupe de Pathologie Infectieuse Pédiatrique, Nice, France.

PMID: 39208834
DOI: 10.1016/S2352-4642(24)00228-1

Comment

Nirsevimab-a breakthrough in respiratory syncytial virus bronchiolitis

Zein Assad et al. Lancet Child Adolesc Health. 2024 Oct.

. 2024 Oct;8(10):708-709.

doi: 10.1016/S2352-4642(24)00228-1. Epub 2024 Aug 26.

Authors

Zein Assad¹, Jesse Papenburg², Naïm Ouldali³

Affiliations

¹ Department of General Pediatrics, Pediatric Infectious Disease and Internal Medicine, Robert Debré University Hospital, APHP, Paris, France; Department of Pediatrics, Cayenne Hospital, Cayenne, French Guiana, France; Infection, Antimicrobials, Modelling, Evolution Research Unit, INSERM UMR 1137, Paris Cité University, 75018 Paris, France; Groupe de Pathologie Infectieuse Pédiatrique, Nice, France. Electronic address: zein.assad@aphp.fr.
² Division of Pediatric Infectious Diseases, Department of Pediatrics, Montreal Children's Hospital of the McGill University Health Centre, Montreal, QC, Canada.
³ Department of General Pediatrics, Pediatric Infectious Disease and Internal Medicine, Robert Debré University Hospital, APHP, Paris, France; Infection, Antimicrobials, Modelling, Evolution Research Unit, INSERM UMR 1137, Paris Cité University, 75018 Paris, France; Groupe de Pathologie Infectieuse Pédiatrique, Nice, France.

PMID: 39208834
DOI: 10.1016/S2352-4642(24)00228-1

No abstract available

PubMed Disclaimer

Conflict of interest statement

JP reports research grants from Merck and MedImmune and personal fees from AstraZeneca and Merck. NO is funded by the 2023 ATIP–Avenir partnership between the French National Institute for Health and Medical Research and the French National Center for Scientific Research and reports travel grants from GlaxoSmithKline, Pfizer, MSD, and Sanofi. ZA declares no competing interests.

Comment on

Real-world effectiveness of nirsevimab immunisation against bronchiolitis in infants: a case-control study in Paris, France.
Carbajal R, Boelle PY, Pham A, Chazette Y, Schellenberger M, Weil C, Colas AS, Lecarpentier T, Schnuriger A, Guedj R, Lorrot M, Corvol H, Enault M. Carbajal R, et al. Lancet Child Adolesc Health. 2024 Oct;8(10):730-739. doi: 10.1016/S2352-4642(24)00171-8. Epub 2024 Aug 26. Lancet Child Adolesc Health. 2024. PMID: 39208832
Effect of nirsevimab on hospitalisations for respiratory syncytial virus bronchiolitis in France, 2023-24: a modelling study.
Brault A, Pontais I, Enouf V, Debeuret C, Bloch E, Paireau J, Rameix-Welti MA, White M, Baudemont G, Lina B, Parent du Châtelet I, Casalegno JS, Vaux S, Cauchemez S. Brault A, et al. Lancet Child Adolesc Health. 2024 Oct;8(10):721-729. doi: 10.1016/S2352-4642(24)00143-3. Epub 2024 Aug 26. Lancet Child Adolesc Health. 2024. PMID: 39208833

References

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science
Medical
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Nirsevimab-a breakthrough in respiratory syncytial virus bronchiolitis

Affiliations

Nirsevimab-a breakthrough in respiratory syncytial virus bronchiolitis

Authors

Affiliations

Conflict of interest statement

Comment on

References

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Medical